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Recently, significant numbers of individuals with primary human immunodeficiency virus (HIV) infection
have been found to harbor viral strains with reduced susceptibility to antiretroviral drugs. In one study, HIV
from 16% of such antiretroviral-naive individuals was shown to have a susceptibility to nonnucleoside reverse
transcriptase (RT) inhibitors (NNRTIs) between 2.5- and 10-fold lower than that of a wild-type control.
Mutations in the RT domain that had previously been associated with antiretroviral resistance were not shared
by these strains. We have analyzed by logistic regression 46 variable amino acid sites in RT for their effect on
susceptibility and have identified two novel sites influencing susceptibility to NNRTIs: amino acids 135 and 283
in RT. Eight different combinations of amino acids at these sites were observed among these patients. These
combinations showed a 14-fold range in mean susceptibility to both nevirapine and delavirdine. In vitro
mutagenesis of the control strain combined with a phenotypic assay confirmed the significance of amino acid
variation at these sites for susceptibility to NNRTIs.
Since the first reports of sexual transmission of antiretrovi-
ral-resistant strains of human immunodeficiency virus (HIV)
(1, 3, 5), there has been concern over the extent to which the
possibility of infection with drug-resistant strains might preju-
dice the successful treatment of HIV-infected individuals.
Studies of transmission occurring when zidovudine (ZDV)
monotherapy was the predominant treatment indicated that
mutations at amino acid sites associated with ZDV resistance
were present in up to 10% of untreated individuals (16, 19).
Antiretroviral-naive HIV-infected individuals with mutations
associated with reduced susceptibility to nonnucleoside reverse
transcriptase (RT) inhibitors (NNRTI) and protease (PR) in-
hibitors have also been reported (8, 10).
The introduction of potent antiretroviral therapy has had a
major impact on the morbidity and mortality associated with
HIV disease (15), but the efficacy of combination therapy is
impaired if strains resistant to the component drugs are
present (14). Recent studies of the prevalence of reduced sus-
ceptibility to antiretrovirals among patients with primary HIV
infection have addressed the question in patients infected since
combination therapy became the standard of care (21, 26). The
studies of Boden et al. (2) and Little et al. (13) analyzed 80 and
141 patients, respectively, all infected in major cities in the
United States. These studies revealed that while strains with
large reductions in susceptibility were infrequent in primary
infection (;3%), strains of intermediate susceptibility were
more common. In particular, Little et al. (13) found, using a
highly reproducible phenotypic assay, that 16% of subjects
were infected with strains showing susceptibility to NNRTI
between 2.5- and 10-fold lower than that of the wild-type con-
trol (NL4-3). Surprisingly, only in one case was this phenotypic
difference associated with a mutation at a site previously asso-
ciated with drug resistance.
At least two possible explanations for the appearance of
moderate reductions of susceptibility in significant numbers of
individuals in this study can be proposed. According to the
first, suggested by the association of many of these individuals
with a subset of the clinics participating in this study, a pro-
portion of these individuals are infected with phylogenetically
related viral strains through previously unknown transmission
networks, and these strains share reduced susceptibility as a
result of their common ancestry. Under the second hypothesis,
the high prevalence of reduced susceptibility is due to poly-
morphic variants at amino acid sites which have not previously
been associated with antiretroviral resistance, acting either
alone or in combination. We have assessed the merits of the
first of these two alternatives by performing a phylogenetic
analysis of the nucleotide sequences of the viral RT and PR
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coding regions of the pol gene, and we have investigated the
second by a logistic regression analysis of the association be-
tween variation at polymorphic amino acid sites and phenotype
for each drug. The former analysis did not support the possi-
bility that strains with reduced susceptibility to NNRTIs shared
a common infection source. The latter indicated that novel
sites, not previously linked with resistance to these antiretro-
virals, were significantly associated with reduced drug suscep-
tibility. The mutations identified were then tested by in vitro
mutagenesis studies, which confirmed both their identity and
the scale of effect.
MATERIALS AND METHODS
Patient characteristics. Sequence data were determined for the RT and PR
coding regions from plasma samples collected from a subset of 110 patients from
the original cohort of 141 subjects (13). All subjects signed an informed consent
for study participation which had been approved by the local Institutional Hu-
man Subjects Committee. Patients with clinical or laboratory evidence of primary
HIV infection were referred to participating study centers. Documentation of
HIV seroconversion was available for 71% of the original 141-patient cohort.
Primary HIV infection was presumed in the remaining subjects based on docu-
mentation of a positive HIV serology following an acute retroviral illness and a
negative HIV antibody test (undocumented) during the previous 12 months.
Study participants were predominantly men who reported a history of sex with
men; they were enrolled between 1989 and 1998, though only 19 (17%) were
identified prior to 1996. A baseline plasma sample was collected from each of the
110 subjects an average of 62 days (range, 0 to 279 days) after the estimated date
of HIV infection and stored at 270°C. None of the subjects had received more
than 7 days of antiretroviral therapy prior to study entry and analysis of antiret-
roviral susceptibility.
Phenotypic determination of antiretroviral susceptibility. Patient virus drug
susceptibility was measured by the PhenoSense HIV assay (17). Briefly, PR and
RT coding sequences were amplified by RT-PCR and cloned into a recombinant
HIV vector containing a luciferase reporter gene using restriction enzymes ApaI
and PinAI. The resistance test vectors (RTVs) were transfected into 293 cells;
virus was harvested and used to infect fresh 293 cells in the presence and absence
of drug. The concentration of drug required to inhibit viral replication by 50% in
a single cycle assay was determined with reference to that of a drug-sensitive
reference strain (CNDO) containing PR and RT coding sequences from the
laboratory HIV strain NL4-3. Overall, the assay is reproducible within a 2.5-fold
range (17). With respect to NNRTIs specifically, the coefficient of variation
(standard deviation/mean) for 27 replicates of multiple patient and three refer-
ence samples lay between 7 and 12% (N. Hellmann, et al., Abstr. 3rd Int.
Workshop HIV Drug Resist. Treat. Strategies, abstr. 51, 1999). Susceptibility to
a panel of 15 antiretrovirals was performed for patient virus samples. Suscepti-
bility to delavirdine, efavirenz, and nevirapine was determined for the site-
directed mutants in RT.
Genotype determination was performed by consensus ABI sequencing of, in
most cases, the PCR amplicon used in the PhenoSense assay, using Taq poly-
merase and Big Dye terminators (Perkin-Elmer, Foster City, Calif.) with se-
quences edited using Sequencher software (Gene Codes Corp., Ann Arbor, Mich.).
Additional genotyping was obtained for some susceptible patients by direct
consensus sequencing of the PCR-amplified product from plasma viral RNA.
Nucleotide sequence data were aligned using the BioEdit version 4.5.8 (T. Hall,
North Carolina State University) and GDE (24) screen-based multiple sequence
editors, translated, and exported as ASCII files.
Site-directed mutagenesis. Mutations were introduced into the RT coding
region of the reference vector (CNDO) using the megaprimer method (22).
Briefly, a sense primer spanning the mutation was used in an amplification
reaction with an antisense primer that anneals to sequences 39 of the mutated
region and spans the PinAI site present in the NL4-3 RT coding region. The
product of the first amplification reaction is used as a megaprimer in a second
PCR in combination with a sense primer that anneals to sequences 59 of the
mutated region and spans the ApaI site in the gag coding region of NL4-3. The
product generated in the second PCR containing the mutated sequence is cloned
into the reference vector using the ApaI and PinAI sites. The sequence of the
entire ApaI-to-PinAI segment of each clone was confirmed by DNA sequencing.
Phylogenetic analysis. Phylogenetic analysis was performed using maximum-
likelihood (6) and neighbor-joining (20) methods as implemented in the PHYLIP
(7) and TREECON (25) software packages, respectively. One thousand boot-
strap resamples of the sequence data set were generated for the neighbor-joining
analysis.
Statistical analysis. Aligned amino acid sequence files were imported into
SPSS version 9.0 (SPSS Inc., Chicago, Ill.) and edited to remove invariant sites.
Statistical analysis was performed on all amino acid sites where a nonconsensus
amino acid was observed in 5 or more individuals out of 110 studied. Effects of
individual amino acids were assessed by logistic regression and one-tailed exact
tests. Combinations of sites contributing to the variation in susceptibility were
identified by logistic regression with stepwise selection and by linear regression
on log-transformed fold change values as described elsewhere (18).
Nucleotide sequence accession numbers. Nucleotide sequences have been
submitted to GenBank under accession no. AF301265 to AF301374.
RESULTS
Phenotypic analysis determined that 13 out of 110 patients
studied had moderate reductions in susceptibility to nevirap-
ine, between 2.5- and 10-fold lower than that of the control
strain, NL4-3, and 19 patients had reduced susceptibility to
delavirdine. Two individuals were identified as having reduced
susceptibility to efavirenz. Moderate reductions in susceptibil-
ity to NNRTIs were not associated with primary resistance-
associated mutations at any of amino acid positions 98, 101,
103, 106, 108, 181, 188, and 190 (13).
Amino acid variation in RT in primary HIV infection.
Among the 302 amino acid sites analyzed in RT, 102 showed a
variant in one or more subjects, and at 63 sites the variant was
present in two or more subjects. Sites where the mutant amino
acid was present in five or more subjects were included in the
regression analysis; 46 amino acid sites met this criterion, of
which 24 had more than one non-wild-type amino acid within
this data set.
Phylogenetic clustering. The phylogenetic analysis was per-
formed on the same 906-bp region of RT used in the analysis
of susceptibility. The tree presented (Fig. 1) was obtained from
analysis of all sites, but including only third base positions did
not change its structure (data not shown). Two sequences were
clearly distinct from all others in the tree. These were identi-
fied as subgroup C viruses by comparison to reference strains
(data not shown). Although the individuals from whom these
strains were obtained were diagnosed with primary HIV infec-
tion in the United States, both had identified HIV exposure in
Africa. Neither virus showed reduced susceptibility to any an-
tiretroviral tested.
No general clustering of patients with reduced susceptibility
was apparent from the tree, but there are a small number of
clusters with strong bootstrap support. Two of these groupings,
both from Los Angeles, each comprised pairs of patients both
of whom showed reduced susceptibility. Although supported in
100% of bootstraps, these sequences were distinct, differing at
1.39 and 1.08% of nucleotide positions, respectively, out of
906. Two other small clusters of drug-susceptible sequences
were identified among individuals from Massachusetts (one
pair) and California (one pair from San Diego linked to an-
other pair comprising one San Diego and one Los Angeles
patient). The pair of patients identified from San Diego self-
reported as a monogamous couple of whom it was previously
believed that one had infected the other. No other linkages
could be established from clinical records. Overall there was no
evidence from the tree that reduced susceptibility was associ-
ated with the transmission of phylogenetically related viruses.
Analysis of amino acid sites conferring reduced susceptibil-
ity. Regression analysis was performed on amino acid identity
at all 46 variable amino acid sites in the RT domain for the 110
RT sequences. Logistic regression on individual sites identified
two sites as significantly associated with reduced susceptibility
to nevirapine, amino acid (aa) 135 (P 5 0.008) and aa 283 (P 5
0.001), of which aa 135 was also significantly associated with
reduced susceptibility to delavirdine (P 5 0.0002) (Table 1).
A single variant amino acid was observed at position 283 in
this data set, Leu3Ile (L283I). Isoleucine was present at this
position in seven samples, five of which were from the 13 cases
showing reduced susceptibility to nevirapine, and three of
which were also among the 19 delavirdine cases. The mean
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changes in susceptibility for the seven strains with 283I were
2.5-fold for nevirapine and 2.35-fold for delavirdine.
Amino acid site 135 was associated with reduced suscepti-
bility to both nevirapine and delavirdine. At this site the con-
sensus amino acid among B-subtype strains of HIV-1 is isoleu-
cine, and four variant amino acids were observed in this data
set (Table 2). One strain, which had a substantially greater
reduction in susceptibility to both drugs than any other, had a
methionine at this site, which was not observed in any other
strains. This strain also had the only example of a mutation at
position 138 (138A). Because there were too few variant
strains, 138 was not included in this analysis. Although the
phenotype of the 138A mutation has not been described, other
mutations at this site are known to be associated with highly
reduced susceptibility to nonnucleoside drugs (23), and so this
strain was not included in further analyses. The second most
common amino acid at position 135, threonine (I135T), was
observed in 26 individuals (24%) and on its own was associated
with mean fold changes of 2.2 to nevirapine and 2.5 to dela-
virdine. The 135T mutation was found in 11 of the 19 instances
of reduced susceptibility to delavirdine and in 8 of the 13
nevirapine cases.
The five alternative amino acids at 135 and two at 283
specify a potential 10 different genotypes at the pair of sites, of
which 7 were observed in this data set. Using data at both sites
in the analysis gave further information about susceptibility.
Thus, of the seven strains with 283I, the three that were wild
type at 135 had a mean fold change of 2.0 for nevirapine, while
those with 135T had an almost 50% greater reduction in mean
susceptibility (2.9-fold; n 5 4) (Table 3). Strains that were
135T and wild type at 283 also showed a mean susceptibility
reduction of 2.0-fold. However, not all mutations at these sites
were associated with reduced susceptibility, and the suscepti-
bilities to the two drugs were not always concordant. In par-
ticular, 135V showed little change in susceptibility to delavir-
dine but an increased susceptibility to nevirapine relative to the
wild-type control (0.5-fold; n 5 5) (Table 3). Taken together,
genotype at aa 135 and 283 explained 15% of the variation in
susceptibility to nevirapine and 9% of the variation in suscep-
tibility to delavirdine in this data set.
Phenotypic testing of site-directed mutants. RTVs contain-
ing mutations at the amino acid sites that were identified by the
regression analysis, both alone and in combination, were con-
structed in vitro. The isoleucine (I) at 135 of RT in NL4-3 was
mutated to each of the five different amino acids that were
found in patient viruses, leucine (L), threonine (T), methio-
nine (M), arginine (R), and valine (V). RTVs containing M, L,
or T at 135 alone showed very small reductions in susceptibility
to the NNRTIs tested, while RTVs containing R or V at 135
FIG. 1. Phylogenetic tree of RT sequences from patients with primary HIV
infection. An unrooted maximum-likelihood phylogenetic tree for all 110 se-
quences analyzed is shown. The two outgroup sequences at the base of the tree
belong to HIV-1 subtype C; all others are subtype B. Bootstrapped neighbor-
joining trees gave essentially the same topology, and the number of bootstrap
resamples supporting internal clusters (out of 1,000) is shown for all cases above
500. Symbols represent virus with wild-type (E) and reduced (F) susceptibility to
NNRTI in the PhenoSense HIV assay. IC50, 50% inhibitory concentration.
TABLE 1. Individual amino acid sites associated with reduced
susceptibility to antiretrovirals in subjects with
primary HIV infectiona
Antiretroviral Amino acid Odds ratio P Exact test P
Nevirapine 283 28.1 0.001 ,0.003
135 5.5 0.008 0.005
Delavirdine 135 8.5 0.0002 ,0.0001
a All sites where P was ,0.01 are shown; in view of the number of tests
performed, probability values higher than 0.01 were not considered significant.
TABLE 2. Mean fold change in susceptibility to nevirapine and
delavirdine associated with variant amino acids at
residue 135 in the RT coding region
Amino acid na %
Mean fold change
Nevirapine Delavirdine
Ib 72 66 1.03 1.4
T 27 25 2.20 2.52
V 6 5.5 0.66 1.80
L 3 2.8 1.09 1.69
Mc 1 0.9 6.96 20.28
a Total scored 5 109.
b Amino acid in NL4-3.
c This strain also had 138A in RT.
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showed a slight increase in NNRTI susceptibility. RTVs con-
taining the L283I substitution alone also showed no significant
decrease in susceptibility to NNRTIs. However, those contain-
ing the L283I substitution in combination with the I135M or -L
substitution showed a four- to fivefold decreases in suscepti-
bility to all three of the NNRTIs tested (Table 4), while the
135T 1 283I constructs showed a smaller but still significant
decrease. These results confirm the role of the mutations iden-
tified from the regression analysis in conferring reduced sus-
ceptibility of HIV-1 RT to NNRTIs when present in combina-
tion.
DISCUSSION
The majority of cases of drug-resistant HIV arise de novo in
the treated patient as a consequence of the error-prone nature
of viral replication and the high replication rate seen in the
viral population. However, transmission of drug-resistant virus
has been described in many studies ranging from ZDV resis-
tance when ZDV monotherapy was widespread to the trans-
mission of multidrug-resistant virus described in recent studies.
Within the context of potent antiretroviral therapy, the trans-
mission of drug-resistant virus remains a significant issue as the
success of combination antiretroviral regimens in the manage-
ment of HIV disease is prejudiced if the patient has been
infected with a virus which is already resistant to one of the
component drugs. Virological failure of combination therapy is
known to develop more rapidly in the presence of resistance to
component drugs (4).
In smaller early surveys of the prevalence of drug resistance
in newly infected individuals (16, 19), it was suggested that up
to 10% of individuals might be infected with ZDV-resistant
virus. Four recently published large studies of the prevalence
of resistance to a number of drugs suggest that the frequency
of transmission of strains showing high levels of drug resistance
may be of the order of 5% for each of the major classes of
antiretrovirals (2, 13, 21, 26). However, in addition to this
lower prevalence of strains with .10-fold reductions in sus-
ceptibility, Little et al. recently showed, using a highly repro-
ducible phenotypic assay, a much higher prevalence of strains
with susceptibility 2.5- to 10-fold lower than that of the control,
especially to NNRTIs and PR inhibitors (13). Where equiva-
lent data were available, similar observations were obtained in
other studies (2, 26).
The reduced susceptibility described was not associated with
mutations at amino acid sites that were previously known to
affect susceptibility to NNRTIs, and its genotypic basis re-
mained unclear. We therefore extended the analysis to all 46
amino acid sites that showed significant variation in a data set
of 110 HIV RT sequences from patients with primary infec-
tion, using logistic regression to detect associations between
individual sites and susceptibility. This approach identified two
novel sites, aa 135 and 283, with strong associations with
NNRTI susceptibility which were then tested by in vitro mu-
tagenesis. This confirmed that specific combinations of non-
wild-type amino acids at these two sites reduced susceptibility
to NNRTIs (Table 4). While this established that the pheno-
typic susceptibility differences are due to genetic variation at
these sites, it is not known by what mechanism the phenotypic
effect is mediated. It is likely that mutations at aa 135 affect
NNRTI susceptibility by virtue of their proximity, in p51, to the
NNRTI binding site (9, 11), but aa 283 is located near the tip
of the thumb domain in RT, and at present its role is unclear.
The high prevalence of reduced susceptibility to NNRTIs in
newly infected individuals raised questions about whether
there were particular clusters or transmission networks within
which individuals were becoming infected with these strains at
high frequency. A molecular epidemiological analysis of the
sequence data showed no clustering of strains with reduced
susceptibility (Fig. 1), although a few small clusters were iden-
tified. In most cases, due to the prevalence of individuals re-
porting anonymous sex as a risk activity, these pairs could not
be explained from the available clinical data, but one pair of
sequences derived from the two members of a long-term sexual
partnership. From this finding we conclude that there was
sufficient phylogenetic information in the data for a cluster of
strains with reduced susceptibility to have been detected if it
had existed.
It has only recently become possible to detect phenotypic
susceptibility differences in the range discussed here, and so
knowledge of their historic prevalence is limited. In particular,
it is not currently possible to determine whether variation at
these sites is related to the use of NNRTIs in the treatment of
HIV in the United States since 1995. However, we note that in
some other HIV clades, the amino acid variants that we have
found to be associated with NNRTI susceptibility are common
(12). Thus, it seems likely that the variation at these positions
among B-subtype sequences represents natural polymorphism
and predated NNRTI therapy. The clinical consequences of
this naturally occurring variation in susceptibility for treatment
response remain to be determined.
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